SLFN11 and cancer: A borderline significant association with shorter PFI was observed for stage IVa versus IIIc cancer (HR = 3.19, 95% CI = 0.89–11.46, P = 0.0758), whereas an opposite trend was found for higher total CD8+ TIL count (HR = 0.67, 95% CI = 0.41–1.09, P = 0.1040) and SLFN11 H-score assessed in cancer cells only (HR = 0.62, 95% CI = 0.38–1.02, P = 0.0620).